Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 15 of 15 matching drugs for PDE10A — including drugs targeting any of its 10 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
dipyridamole, fluorouracil, leucovorin calcium, mitomycin c PDE10A Direct 1
pentoxifylline PDE10A Direct yes 0
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CSK SSL via CSK 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment CSK SSL via CSK 2
afatinib, dasatinib, palbociclib, everolimus, olaparib CSK SSL via CSK 1
bevacizumab, dasatinib, placebo CSK SSL via CSK 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride CSK SSL via CSK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method CSK SSL via CSK 1
dasatinib, laboratory biomarker analysis, physiologic testing CSK SSL via CSK 1
dasatinib, mfolfox6 CSK SSL via CSK 1
dasatinib, pharmacological study CSK SSL via CSK 1
dasatinib, temozolomide, placebo, radiation therapy CSK SSL via CSK 1
gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy NFKB2 SSL via NFKB2 1
sulfasalazine NFKB2 SSL via NFKB2 1
ataluren RPL22 SSL via RPL22 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.